 [10] 
  Finally, while Prothonotary Tabib suggested in her reasons that Pfizer will likely be able to respond to Dr. Moe’s affidavit in cross-examination, Pfizer argues that the Court has recognized that cross-examination “is no substitute” for written reply evidence: AstraZeneca, above, at paragraph 31. Pfizer therefore submits that on hearing the matter de novo, the Motions Judge should grant it leave to file Dr. Husain’s reply affidavit. 
 
 